Literature DB >> 25331835

Comparative proteomics among cytochrome p450 family 1 for differential substrate specificity.

Siddharth S Kesharwani1, Prajwal P Nandekar, Preeti Pragyan, Abhay T Sangamwar.   

Abstract

Apart from playing key roles in drug metabolism and adverse drug-drug interactions, CYPs are potential drug targets to treat a variety of diseases. The intervention of over expression of P450 1A1 (CYP1A1) in tumor cells is identified as a novel strategy for anticancer therapy. We investigated three isoforms of CYP1 family (CYP1A1, CYP1A2, and CYP1B1) for their substrate specificity. The understanding of macromolecular features that govern substrate specificity is required to understand the interplay between the protein function and dynamics. This can help in design of new antitumor molecule specifically metabolized by CYP1A1 to mediate their antitumor activity. In the present study, we carried out the comparative protein structure analysis of the three isoforms. Sequence alignment, root mean square deviation (RMSD) analysis, B-factor analysis was performed to give a better understanding of the macromolecular features involved in substrate specificity and to understand the interplay between protein dynamics and functions which will have important implications on rational design of anticancer drugs. We identified the differences in amino acid residues among the three isoforms of CYP1 family, which may account for differential substrate specificity. Six putative substrate recognition sequences are characterized along with the regions they form in the protein structure. Further the RMSD and B-factor analysis provides the information about the identified residues having the maximum RMSD and B-factor deviations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25331835     DOI: 10.1007/s10930-014-9586-6

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  16 in total

Review 1.  Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling.

Authors:  Dong Dong; Baojian Wu
Journal:  Drug Metab Rev       Date:  2012-02       Impact factor: 4.518

Review 2.  Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases.

Authors:  Eric F Johnson; C David Stout
Journal:  Biochem Biophys Res Commun       Date:  2005-09-02       Impact factor: 3.575

Review 3.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors.

Authors:  S Rendic; F J Di Carlo
Journal:  Drug Metab Rev       Date:  1997 Feb-May       Impact factor: 4.518

4.  Preferred binding orientations of phenacetin in CYP1A1 and CYP1A2 are associated with isoform-selective metabolism.

Authors:  Qingbiao Huang; Rahul S Deshmukh; Spencer S Ericksen; Youbin Tu; Grazyna D Szklarz
Journal:  Drug Metab Dispos       Date:  2012-09-04       Impact factor: 3.922

5.  Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1.

Authors:  An Wang; Uzen Savas; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2010-12-08       Impact factor: 5.157

6.  Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.

Authors:  M S Chua; E Kashiyama; T D Bradshaw; S F Stinson; E Brantley; E A Sausville; M F Stevens
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

7.  Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis.

Authors:  B C Lewis; P I Mackenzie; J O Miners
Journal:  Arch Biochem Biophys       Date:  2007-09-26       Impact factor: 4.013

Review 8.  Modulation of carcinogen-metabolizing cytochromes P450 by phytochemicals in humans.

Authors:  Wanda Baer-Dubowska; Hanna Szaefer
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-05-02       Impact factor: 4.481

9.  Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2.

Authors:  Mary J Kuffel; Jennifer C Schroeder; Lori J Pobst; Stephen Naylor; Joel M Reid; Scott H Kaufmann; Matthew M Ames
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

Review 10.  Cytochrome p450 and chemical toxicology.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2007-12-06       Impact factor: 3.739

View more
  1 in total

Review 1.  Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date.

Authors:  Jayalakshmi Sridhar; Navneet Goyal; Jiawang Liu; Maryam Foroozesh
Journal:  Molecules       Date:  2017-07-08       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.